Objective To analyze the safety of combined oxaliplatin and S-1 in postoperative adjuvant chemotherapy for gastric cancer.Methods Retrospective analysis was conducted to clinical data of gastric cancer patients who received the combined oxaliplatin and S-1 in postoperative adjuvant chemotherapy in our hospital between January 2008 and December 2012.The adverse reactions and tolerance were observed after postoperative adjuvant chemotherapy.Results The most common adverse reactions of postoperative adjuvant chemotherapy for gastric carcinoma included reduction of neutrophils (67.3 ％),nausea and vomiting (61.6 ％),and reduction of white blood cells (59.6 ％).3-4 degree adverse reactions included the reduction of platelets (21.2 ％),reduction of neutrophils(19.2 ％),nausea and vomiting (7.7 ％),and decreased appetite (5.8 ％).Conclusion The combined oxaliplatin and S-1 in postoperative adjuvant chemotherapy for gastric cancer can improve the survival rate,but attention should be paid to tolerance and adverse reactions.%目的 探讨奥沙利铂联合替吉奥用于胃癌术后辅助化疗的安全性.方法 回顾性分析本院2008年1月-2012年12月采用奥沙利铂联合替吉奥方案进行胃癌术后辅助化疗的52例患者的临床资料,观察辅助化疗后的不良反应及耐受情况.结果 胃癌术后辅助化疗最常见的不良反应依次为中性粒细胞降低(67.3％),恶心、呕吐(61.6％),白细胞降低(59.6％);3～4度不良反应依次为血小板降低(21.2％),中性粒细胞降低(19.2％),恶心、呕吐(7.7％)和食欲下降(5.8％).结论 奥沙利铂联合替吉奥用于晚期胃腺癌术后辅助化疗可提高患者生存率,但应注意术后化疗的耐受性和不良反应.
展开▼
